首页> 外文期刊>ACS Chemical Biology >Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation
【24h】

Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation

机译:通过联合哺乳动物细胞工程和化学酶转基因组合的人促红细胞生成素(EPO)的聚糖重新凝固

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The tremendous structural heterogeneity of N-glycosylation of glycoproteins poses a great challenge for deciphering the biological functions of specific glycoforms and for developing protein-based therapeutics. We have previously reported a chemoenzymatic glycan remodeling method for producing homogeneous glycoforms of N-glycoproteins including intact antibodies, which consist of endoglycosidase-catalyzed deglycosylation and novel glycosynthase-catalyzed transglycosylation, but its application to complex glycoproteins carrying multiple N-glycans remains to be examined. We report here site-selective chemoenzymatic glycosylation remodeling of recombinant human erythropoietin (EPO) that contains three N-glycans. We found that the generation of a HEK293S GnT I knockout FUT8 overexpressing cell line enabled the production of an unusual Man5GlcNAc2Fuc glycoform, which could be converted to the core-fucosylated GlcNAc-EPO intermediate acceptor for enzymatic transglycosylation. With this acceptor, homogeneous sialylated glycoform or azide-tagged glycoform were produced using the glycosynthase (EndoF3-D165A) catalyzed transglycosylation. Interestingly, a remarkable site-selectivity was observed in the transglycosylation reactions, leading to the introduction of two N-glycans selectively at the Asn-38 and Asn-83 sites, which was confirmed by a detailed MS/MS analysis of the transglycosylation product. Finally, a different N-glycan was attached at the third (Asn-24) site by pushing the enzymatic transglycosylation with a distinct glycan oxazoline, achieving the site-selective glycosylation modification of the protein. This study represents the first example of site-selective chemoenzymatic glycan engineering of complex glycoproteins carrying multiple N-glycans.
机译:糖蛋白的N-糖基化的巨大结构异质性造成了巨大的挑战,用于解密特定糖族的生物学功能和用于显影基于蛋白质的治疗剂。我们先前已经报道了一种化学酶聚糖改造方法,用于产生N-糖蛋白的均匀糖蛋白,包括完整的抗体,其包括内糖苷酶催化的脱糖基化和新的糖合酶催化的转基质化,但其对携带多种N-聚糖的复合糖蛋白的应用仍有待检查。我们在此报道含有三种N-聚糖的重组人促红细胞生成素(EPO)的遗址选择性化学酶糖基化重塑。我们发现,HEK293S GNT I淘汰FUT8过表达细胞系的产生使得能够产生不寻常的MAN5GLCNAC2FUC糖糖,其可以转化为酶 - 岩石化的GLCNAC-EPO中间受体,用于酶促糖基化。利用该受体,使用糖合作酶(endof3-D165a)催化的转基质化产生均匀的唾液酸化糖蛋白或叠氮化糖型糖族。有趣的是,在常糖基化反应中观察到显着的位点选择性,导致在ASN-38和ASN-83位点中选择性地引入两种N-聚糖,通过对常糖基化产物的详细MS / MS分析来证实。最后,通过用不同的聚糖恶唑啉通过不同的甘油糖基化,在第三(ASN-24)位点上附着不同的N-聚糖,从而实现蛋白质选择性糖基化改性的位点选择性糖基化改性。该研究代表了携带多种N-聚糖的复合糖蛋白的位点选择性化学酶聚糖工程的第一实例。

著录项

  • 来源
    《ACS Chemical Biology》 |2017年第6期|共9页
  • 作者单位

    Univ Maryland Dept Chem &

    Biochem College Pk MD 20742 USA;

    US FDA Ctr Biol Evaluat &

    Res Silver Spring MD 20993 USA;

    Univ Maryland Dept Chem &

    Biochem College Pk MD 20742 USA;

    Univ Maryland Dept Chem &

    Biochem College Pk MD 20742 USA;

    Univ Maryland Dept Chem &

    Biochem College Pk MD 20742 USA;

    US FDA Ctr Biol Evaluat &

    Res Silver Spring MD 20993 USA;

    Univ Maryland Dept Chem &

    Biochem College Pk MD 20742 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号